Actively Recruiting
Study of Low-Dose Naltrexone to Treat Complex Regional Pain Syndrome in Adults Aged 18 to 70
Led by Stanford University · Updated on 2025-05-29
120
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating low-dose naltrexone LDN as a potential treatment for symptom relief in people with complex regional pain syndrome CRPS. This study compares LDN with a placebo to understand their effects on pain severity. Participants will be randomly assigned to one of the two groups in this interventional trial. Participants will take either 4.5 mg of naltrexone hydrochloride once daily or a sugar pill as a placebo for several weeks. The study is designed with quadruple masking to ensure unbiased results. Participants will attend study visits either in person or virtually and complete questionnaires during the treatment period. Throughout the study, participants will be monitored for changes in their pain severity, with primary outcomes measured approximately four weeks after the treatment ends. The study involves questionnaires and follow-up visits to assess symptom changes. The entire process is overseen by Stanford University, and participants will be involved until the study concludes in July 2027.
CONDITIONS
Brief Title
Low-Dose Naltrexone for the Treatment of Complex Regional Pain Syndrome
Research Team
B
Birute Gedrimaite
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here